MCAS and Fibromyalgia: The Mast Cell-Pain Connection

Mast cell activation syndrome (MCAS) and fibromyalgia co-occur at rates of 30–50% in clinical populations, and the relationship between them is increasingly understood to be mechanistic rather than coincidental. Mast cells play a direct role in central sensitization — the pain amplification process that underlies fibromyalgia — and treating MCAS often produces significant improvement in fibromyalgia symptoms.

How Mast Cells Drive Central Sensitization

Central sensitization is the process by which the central nervous system becomes hypersensitive to pain signals, amplifying normal sensory inputs into painful experiences. It is the core mechanism of fibromyalgia, explaining why patients experience widespread pain from stimuli (touch, pressure, temperature) that would not be painful in healthy individuals.

Mast cells contribute to central sensitization through multiple pathways:

Neuroinflammation. Mast cells in the brain and spinal cord (called "brain mast cells") release histamine, cytokines, and other mediators that activate microglia and astrocytes, creating a neuroinflammatory environment that lowers the pain threshold. Elevated mast cell activity in the dorsal horn of the spinal cord — the first relay station for pain signals — directly amplifies pain transmission.

Substance P and CGRP. Mast cells release substance P and CGRP, neuropeptides that sensitize pain receptors (nociceptors) throughout the body. Elevated substance P is one of the most consistent findings in fibromyalgia research, and mast cell activation is a major source of substance P.

Peripheral sensitization. Mast cells in skin, muscle, and connective tissue release mediators that sensitize peripheral nociceptors, lowering the threshold for pain signals that are then amplified by the already-sensitized central nervous system.

HPA axis dysregulation. Mast cell-derived CRH (corticotropin-releasing hormone) activates the hypothalamic-pituitary-adrenal (HPA) axis, contributing to the cortisol dysregulation and stress hypersensitivity seen in fibromyalgia.

Clinical Clues That MCAS Is Driving Fibromyalgia

Fibromyalgia patients with significant MCAS contribution often have:

• Pain that worsens after eating (particularly high-histamine foods)
• Pain that worsens with heat, exercise, or stress (common MCAS triggers)
• Episodic flushing, urticaria, or itching alongside pain flares
• Significant gastrointestinal symptoms (IBS-like)
• Reactions to medications, supplements, or environmental triggers
• Improvement with antihistamines (even partial improvement is significant)

Treatment Implications

Antihistamines for fibromyalgia. Multiple case series and small trials have reported improvement in fibromyalgia pain with H1 + H2 antihistamine combinations, particularly in patients with MCAS features. The combination of cetirizine (H1) and famotidine (H2) is commonly used.

Ketotifen. This combined H1 blocker and mast cell stabilizer has been studied in fibromyalgia and shows benefit in some patients, likely through its dual mechanism of blocking histamine effects and preventing mast cell degranulation.

Low-histamine diet. Reducing dietary histamine load during fibromyalgia flares can reduce mast cell activation and improve pain control. This is not a cure but can be a useful adjunct.

Quercetin. A natural flavonoid with mast cell-stabilizing and anti-inflammatory properties. Some fibromyalgia patients report benefit at doses of 500–1,000 mg twice daily.

Addressing triggers. Identifying and avoiding personal MCAS triggers (foods, environmental exposures, medications) can reduce the frequency and severity of fibromyalgia flares.

ChatDys resources: Track your pain flares alongside potential MCAS triggers in the Health Tracker. Review our MCAS Triggers article and Low-Histamine Diet guide. Upload your tryptase and histamine results to Biomarkers.